Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,
Omega Diagnostics Gp (AIM:ODX) US expansion update
Maiden US Laboratory FoodPrint® installation,
Is 2023 HVivo And Harland & Wolff Year
Stock markets in the UK are either heading into a recession or already are. Many investors are concerned about what the future holds for them.
Evgen Pharma PLC (AIM:EVG) Study started of new SFX-01 tablet formulation
First healthy volunteers dosed on schedule
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Omega Diagnostics Gp (AIM:ODX) Positive WHO data received for VISITECT® CD4 test
Test shows high diagnostic accuracy (specificity and sensitivity)
Futura Medical PLC (AIM:FUM) Highly positive FM71 Phase 3 Study Results
Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Omega Diagnostics Gp (AIM:ODX) Change of preliminary results date
Change of preliminary results date and investor presentation and update to CD4 sale
Omega Diagnostics Gp (AIM:ODX) Completion of Sale of the CD4 Business
Completion of Sale of the CD4 Business
Omega Diagnostics Heads of Terms agreed for Sale of CD4 Busines
Omega Diagnostics Group PLC, (AIM: ODX). announced that it has selected a preferred bidder for its CD4 business after having made an announcement nearly two months back.
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep